Landmark Studies

This retrospective review found no increase in cancer mortality rates in uveitis patients with non-infectious uveitis receiving systemic corticosteroids, azathioprine, methotrexate or cyclosporine A.

• POINT

• FAST

• MUST

• SITE

This RCT found that the dexamethasone implant (Ozurdex) was effective in controlling intraocular inflammation in eyes with non-infectious intermediate and posterior uveitis.

• POINT

• HURON

• MUST

• FAST

This RCT found mycophenolate mofetil and methotrexate to be non-inferior to each other in the treatment of non-infectious intermediate, posterior and panuveitis

• POINT

• FAST

• MUST

• SITE

Which of the following statements is TRUE regarding the MUST trial?

• It compared the efficacy and safety of triamcinolone acetonide implant and standard therapy in the treatment of non-infectious intermediate, posterior or panuveitis.

• There was no difference in BCVA between the implant and standard treatment groups

• There were fewer local adverse events in the implant group

• Visual outcomes were worse in the systemic group at 7 years

Which of the following statements is TRUE regarding the VISUAL I trial?

• It assessed the safety and efficacy of adalimumab in patients with active non-infectious intermediate, posterior and panuveitis.

• There was a significantly shorter median time to treatment failure in the adalimumab group compared to placebo.

• Worsening of AC cell grade, vitreous haze grade and BCVA was significantly less common in the placebo group compared to the adalimumab group

• The adalimumab group had significantly more adverse events compared to placebo.

Which of the following statements is FALSE regarding the VISUAL II trial?

• It assessed the safety and efficacy of adalimumab in preventing uveitic flare in patients with inactive non-infectious intermediate, posterior or panuveitis controlled by steroids.

• Time to treatment failure was significantly shorter in the treatment group compared to placebo

• There were significantly fewer cases of treatment failure in the adalimumab group compared to placebo.

• Adalimumab was found to be effective in preventing disease flare-up patients with inactive uveitis

A 35M with chronic unilateral non-infectious intermediate uveitis presented with significant macular edema.  Which of the following statements is TRUE based on the POINT trial?

• Periocular TA injection is as effective as intravitreal steroids at week 4

• Intravitreal dexamethasone implant and intravitreal TA are equally effective in achieving resolution of ME

• The intravitreal dexa implant group had increased risk of IOP elevation compared to the intravitreal TA and periocular TA groups

• Periocular TA group had significantly greater improvements in BCVA compared to the intravitreal steroid groups